Trending...
- Boston Industrial Solutions' Natron® 512N Series UV LED Ink Earns CPSIA Certification
- Roblox and Solsten Alliances; a Stronger Balance Sheet and Accelerated Growth Through AI, Gaming, and Strategic Partnerships for Super League: $SLE
- Best Criminal Defense Attorneys Of 2025 - ELA Awards
~ Congruence Therapeutics, a biotechnology company focused on developing small molecule correctors to rescue aberrant protein function, has announced their participation in the International Congress of Parkinson's Disease and Movement Disorders 2024 Meeting. The event will take place from September 27th to October 1st, 2024 in Philadelphia, PA.
The company's Chief Scientific Officer, Sharath Hegde, Ph.D., shared that mutations of the GBA1 gene are considered the most significant genetic risk factor for Parkinson's Disease. Congruence is dedicated to addressing this issue by utilizing their proprietary platform Revenir™ to discover potent and brain-penetrant allosteric GCase correctors. These molecules have shown promising results in preclinical studies.
More on The PennZone
At the conference, Congruence will present a poster titled "Identification of Allosteric GCase Correctors using Revenir™ for the treatment of GBA1-Parkinson's Disease." The abstract number for this presentation is 791 and it is scheduled for Sunday, September 29th from 1-3PM. Jeremy Dupaul-Chicoine, Associate Director of Biology at Congruence Therapeutics, will be the presenting author.
The company's efforts to develop effective treatments for GBA1-Parkinson's Disease have yielded positive results and they continue to optimize their chemical leads in hopes of discovering potential clinical candidates. This presentation at the International Congress of Parkinson's Disease and Movement Disorders serves as a testament to Congruence Therapeutics' dedication to improving the lives of those affected by this debilitating disease.
The company's Chief Scientific Officer, Sharath Hegde, Ph.D., shared that mutations of the GBA1 gene are considered the most significant genetic risk factor for Parkinson's Disease. Congruence is dedicated to addressing this issue by utilizing their proprietary platform Revenir™ to discover potent and brain-penetrant allosteric GCase correctors. These molecules have shown promising results in preclinical studies.
More on The PennZone
- Sheffield Clinic Highlights Safe, Inclusive Laser Hair Removal While Improving Access
- Appliance EMT Partners with Kids Motel Ministry in Metro Atlanta
- CNCPW Divulga Dados de Liquidez do 1º Trimestre: Confirma 100% de Reservas e Atualiza Protocolos de "Saque CNCPW" Contra Fluxos Ilícitos
- Tech Workers Are Escaping "Forever Layoffs" By Becoming Their Own Boss
- Michael Judkins Releases New Poetry Book, Deeper Than You Think
At the conference, Congruence will present a poster titled "Identification of Allosteric GCase Correctors using Revenir™ for the treatment of GBA1-Parkinson's Disease." The abstract number for this presentation is 791 and it is scheduled for Sunday, September 29th from 1-3PM. Jeremy Dupaul-Chicoine, Associate Director of Biology at Congruence Therapeutics, will be the presenting author.
The company's efforts to develop effective treatments for GBA1-Parkinson's Disease have yielded positive results and they continue to optimize their chemical leads in hopes of discovering potential clinical candidates. This presentation at the International Congress of Parkinson's Disease and Movement Disorders serves as a testament to Congruence Therapeutics' dedication to improving the lives of those affected by this debilitating disease.
Filed Under: Business
0 Comments
Latest on The PennZone
- Sacred Surrogacy, CFC, and Egghelpers Launch Women's Retreats
- The Eichelberger Performing Arts Center Donates Theatrical Lights to Delone Catholic High School
- Moravian Academy Becomes First Pennsylvania School to Partner with Global Sustainability Institute
- Stipenda Appoints David Epstein as Chief Operating Officer
- Woven Wire Mesh as a Durable Filter Medium for Industrial Filtration Systems
- FondoQuantaX Completes Core Trading Engine Upgrade: Refactoring High-Concurrency Architecture with AI Adaptive Algorithms to Navigate Market Extremes
- As Paris Hilton Reclaims Her Icon Status, "Pretty Pop Star" Reemerges to Battle the Age of AI Music
- Food Journal Magazine Is Shaping the Conversation Around Los Angeles Food in 2026
- MITSUYA PLATING Expands ONE-STOP Service for US-based Medical Device, Semiconductor and Aerospace Manufacturers
- Chester County Tile Expert Reveals Top Home Value Mistakes Homeowners Make During Remodeling Projects
- Star Trek, Goonies, Ninja Turtles Stars Among First Main Wave Of FAN EXPO Philadelphia Celebrities
- Voiset AI Planner Launches Smart Booking: Real Estate Agents, ADHD Coaches, Sales Teams End Calendar Chaos
- Max Tucci Makes His Highly-Anticipated Debut On QVC—unveiling A Bespoke Luxury Chocolate Collection Inspired By 100 Years Of Tucci Hospitality
- Vehicledle Launches as Daily Puzzle Game for Car Enthusiasts
- The Ms. Corporate America Maryland Competition Returns for an Unforgettable Evening of Leadership, Excellence, and Empowerment
- Precision Adult Care Expands 24/7 Adult In-Home Care Services to Meet Growing Demand in the Coachella Valley
- Metavalis Launches Massive Community Coat Drive in Branson to Support Local Residents
- Jim Breuer is Coming to The Eichelberger Performing Arts Center This May
- Peak Exteriors to Expand Its Services to Premium Outdoor Lighting Installation
- Ashley Wineland To Release Fiery Full-length Album "Wineland"